Debt-to-Equity Ratio

The debt-to-equity ratio compares a company’s total liabilities to its shareholders’ equity, measuring how much it relies on borrowing versus its own funds.

At 0.13x, Intellia Therapeutics carries very little debt relative to equity, indicating a conservative capital structure. This is well below the healthcare sector median of 0.45x, placing the company in the 30th percentile among its peers—meaning 70% of sector firms have higher leverage. Trend data is not available (N/A for year-over-year and quarter-over-quarter changes), so no directional insight can be drawn. The combination of a low ratio with no trend history suggests low financial risk from debt, but the absence of a track record limits assessment of whether this level is stable or changing. A low debt-to-equity ratio typically supports a neutral investment stance by showing the company is not overleveraged, though the overall NEUTRAL verdict likely reflects other factors such as clinical-stage risks or market conditions.

Frequently Asked Questions

Closest Sector Peers